A Phase 2 Study of Immunogenicity, Safety and Tolerability of CSL412 in Elderly Participants

A Phase II, Double-Blind, Randomised, Controlled, Multi-Centre Study to Evaluate the Immunogenicity, Safety and Tolerability of Three Formulations of CSL412 in Adults (≥ 18 to ≤ 45 Years) and Older Adults (≥ 60 Years)

Current influenza vaccines have a reduced efficacy in the elderly. This study will investigate the immunogenicity, safety and tolerability of an adjuvanted influenza vaccine in elderly participants.

Inclusion Criteria:

• Aged ≥ 18 to ≤ 45 OR ≥ 60
• Ability to provide pre-vaccination venous blood sample

Exclusion Criteria:

• History of clinically significant medical conditions
• Immunomodulative therapy
• Acute infection